Johnson & Johnson $JNJ Stock: Ethic Inc. Grows Stake

Ethic Inc. lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 20.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 132,061 shares of the company’s stock after acquiring an additional 22,303 shares during the quarter. Ethic Inc.’s holdings in Johnson & Johnson were worth $34,962,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the stock. 180 Wealth Advisors LLC grew its position in shares of Johnson & Johnson by 88.6% in the third quarter. 180 Wealth Advisors LLC now owns 24,052 shares of the company’s stock valued at $6,367,000 after purchasing an additional 11,301 shares during the last quarter. Buckhead Capital Management LLC increased its stake in shares of Johnson & Johnson by 10.2% in the third quarter. Buckhead Capital Management LLC now owns 25,466 shares of the company’s stock worth $6,742,000 after purchasing an additional 2,351 shares during the period. StoneX Group Inc. lifted its position in shares of Johnson & Johnson by 5.1% during the 3rd quarter. StoneX Group Inc. now owns 28,581 shares of the company’s stock worth $7,564,000 after purchasing an additional 1,380 shares during the last quarter. Pictet Asset Management Holding SA lifted its position in shares of Johnson & Johnson by 0.6% during the 3rd quarter. Pictet Asset Management Holding SA now owns 1,864,710 shares of the company’s stock worth $493,666,000 after purchasing an additional 11,452 shares during the last quarter. Finally, Verus Capital Partners LLC boosted its stake in Johnson & Johnson by 6.0% during the 3rd quarter. Verus Capital Partners LLC now owns 8,026 shares of the company’s stock valued at $2,125,000 after purchasing an additional 456 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Buying and Selling

In other news, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. This trade represents a 56.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jennifer L. Taubert sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the sale, the executive vice president owned 194,451 shares in the company, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Up 1.4%

Shares of JNJ opened at $276.14 on Friday. The company has a 50-day simple moving average of $265.91 and a 200-day simple moving average of $248.30. The firm has a market capitalization of $664.76 billion, a P/E ratio of 41.84, a P/E/G ratio of 2.73 and a beta of 0.22. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. Johnson & Johnson has a 52 week low of $185.12 and a 52 week high of $282.02.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business had revenue of $25.40 billion during the quarter, compared to analysts’ expectations of $25.38 billion. During the same quarter last year, the company earned $2.80 earnings per share. The firm’s revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities research analysts expect that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a yield of 1.9%. Johnson & Johnson’s dividend payout ratio is 81.21%.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The FDA granted accelerated approval to RYBREVANT FASPRO as a single-agent treatment for certain adults with recurrent or metastatic head and neck cancer after prior platinum chemotherapy and immunotherapy. J&J says the treatment is the first new option in this setting in a decade; trial data showed a 42% response rate. The approval extends the drug’s use beyond lung cancer and could broaden its commercial opportunity, though the indication is limited and accelerated approval may require confirmatory evidence. FDA approval announcement
• Positive Sentiment: J&J’s Innovative Medicine division grew third-quarter sales 7.7% to $16.76 billion, with established blockbusters and new launches more than offsetting generic competition. Continued growth despite patent-related headwinds supports the business outlook. Innovative Medicine sales report
• Neutral Sentiment: J&J was included in an article highlighting companies with a history of dividend increases and strong balance sheets. This reinforces its income-investor appeal, but the article does not identify a new company-specific dividend announcement. Dividend raisers article
• Negative Sentiment: Pomerantz LLP announced it is investigating potential claims on behalf of J&J investors. The notice does not provide details of the claims, but the investigation could add legal and reputational uncertainty. Investor investigation announcement

Analysts Set New Price Targets

A number of research firms have issued reports on JNJ. HSBC raised their target price on Johnson & Johnson from $290.00 to $320.00 and gave the company a “buy” rating in a report on Thursday, September 10th. TD Cowen reiterated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 20th. Citigroup increased their price objective on Johnson & Johnson from $298.00 to $303.00 and gave the company a “buy” rating in a research report on Monday, October 5th. Wall Street Zen downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Finally, Scotiabank restated an “outperform” rating and issued a $305.00 price objective on shares of Johnson & Johnson in a research note on Thursday, July 16th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $275.92.

Johnson & Johnson Company Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech.

Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care.

Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.